Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Insmed stock price, quote, forecast and news

INSM
US4576693075
A1JJA3

Price

76.20
Today +/-
+1.85
Today %
+2.74 %
P

Insmed stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Insmed stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Insmed stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Insmed stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Insmed's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Insmed Stock Price History

DateInsmed Price
8/16/202476.20 undefined
8/15/202474.14 undefined
8/14/202474.87 undefined
8/13/202476.38 undefined
8/12/202474.09 undefined
8/9/202473.98 undefined
8/8/202471.81 undefined
8/7/202470.99 undefined
8/6/202472.68 undefined
8/5/202471.19 undefined
8/2/202471.81 undefined
8/1/202475.33 undefined
7/31/202472.75 undefined
7/30/202472.91 undefined
7/29/202474.56 undefined
7/26/202474.54 undefined
7/25/202474.50 undefined
7/24/202474.43 undefined
7/23/202475.99 undefined

Insmed Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Insmed, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Insmed from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Insmed’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Insmed. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Insmed’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Insmed’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Insmed’s growth potential.

Insmed Revenue, EBIT and net profit per share

DateInsmed RevenueInsmed EBITInsmed Net Income
2029e2.93 B undefined0 undefined785.13 M undefined
2028e2.22 B undefined662.92 M undefined418.85 M undefined
2027e1.54 B undefined123.09 M undefined15.97 M undefined
2026e1.01 B undefined-308.84 M undefined-340.62 M undefined
2025e536.51 M undefined-608.59 M undefined-645.41 M undefined
2024e360.44 M undefined-688.48 M undefined-764.55 M undefined
2023305.21 M undefined-680.93 M undefined-749.57 M undefined
2022245.4 M undefined-478.1 M undefined-481.5 M undefined
2021188.5 M undefined-367.8 M undefined-434.7 M undefined
2020164.4 M undefined-265.2 M undefined-294.1 M undefined
2019136.5 M undefined-235.2 M undefined-254.3 M undefined
20189.8 M undefined-307.3 M undefined-324.3 M undefined
20170 undefined-188.9 M undefined-192.6 M undefined
20160 undefined-173.4 M undefined-176.3 M undefined
20150 undefined-117.5 M undefined-118.2 M undefined
20140 undefined-87.4 M undefined-79.2 M undefined
201311.5 M undefined-55 M undefined-56.1 M undefined
20120 undefined-42.4 M undefined-41.4 M undefined
20114.4 M undefined-35.7 M undefined-68.8 M undefined
20106.9 M undefined-8.1 M undefined-6.4 M undefined
200910.4 M undefined-8.7 M undefined118.4 M undefined
200811.7 M undefined-14.4 M undefined-15.7 M undefined
20077.6 M undefined-20.4 M undefined-20 M undefined
20061 M undefined-47.3 M undefined-56.1 M undefined
2005100,000 undefined-27.4 M undefined-40.9 M undefined
2004100,000 undefined-27.4 M undefined-27.2 M undefined

Insmed Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000.010.010.010.01000.0100000.010.140.160.190.250.310.360.541.011.542.222.93
----------600.0057.14-9.09-40.00-33.33-------1,411.1120.5914.6330.3224.4918.0348.8987.8752.9343.9632.12
----------100.00100.00100.00--------77.7882.3575.6176.6077.5578.36------
000000000071110000000007112124144190239000000
-3-5-8-31-40-19-10-27-27-47-20-14-8-8-35-42-55-87-117-173-188-307-235-265-367-478-680-688-608-3081236620
------950.00----4,700.00-285.71-127.27-80.00-133.33-875.00--500.00-----3,411.11-172.79-161.59-195.21-195.10-222.95-191.11-113.43-30.597.9929.86-
-3-4-7-79-37-36-10-27-40-56-20-15118-6-68-41-56-79-118-176-192-324-254-294-434-481-749-764-645-34015418785
-33.3375.001,028.57-53.16-2.70-72.22170.0048.1540.00-64.29-25.00-886.67-105.081,033.33-39.7136.5941.0749.3749.159.0968.75-21.6015.7547.6210.8355.722.00-15.58-47.29-104.412,686.6787.80
0.10.30.31.83.33.33.63.94.99.511.512.212.7132.523.326.53543.158.661.966.676.984.697.6112.1123140.43000000
---------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Insmed Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Insmed is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (B)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.0100.080.050.030.030.010.020.020.0200.120.110.080.090.110.160.280.160.380.50.490.530.721.150.78
000000000.20.30.10.20.50.80000005.519.216.624.429.741.19
000000000002.100000000000000
000000000.600000000000728.349.66769.983.25
000.30.30.60.20.50.40.50.20.10.20.30.40.62.35.55.25.88.311.320.22428.925.524.18
0.0100.080.050.030.030.010.020.030.0200.120.110.080.090.120.160.290.170.390.520.560.620.841.270.93
0.20.21.61.20.20.10000001.11.91.71.87.58.11012.422.6113.197.295.5102.1104.39
0000000000.302.12.22.10000000005000
00000000000000000000000000
00000000000077.958.258.258.258.258.258.258.258.753.749.373.868.863.7
0016.215.4000000006.30000000000136.1136.1136.11
00.40.30003.33.72.92.32.2000.20.10.30.42.11.324.320.326.85176.196.57
0.20.618.116.60.20.13.33.72.92.62.22.187.562.46060.366.168.469.572.685.6187.1173.3406.4383.1400.77
0.010.010.10.070.030.030.010.020.030.0200.130.20.140.150.180.230.360.240.460.60.740.81.241.661.33
0.10.10.30.30.30.40.40.711.21.21.32.50.20.30.40.50.60.60.80.80.911.21.41.48
0.030.030.20.20.20.210.220.260.320.340.340.350.420.430.460.530.660.90.921.321.491.82.112.672.783.11
-15-22.8-102.6-139.8-176.2-186.5-213.7-254.7-310.8-330.8-346.4-228.1-234.5-294.2-334.8-391.6-470.8-589-765.2-957.9-1,282.2-1,536.5-1,830.6-2,265.2-2,696.6-3,446.15
00200000000-20000000000-1000002001,000800-745
000000000004001,000500000000000000
11.64.496.859.723.426.37.210.513.911.5-2.8123.8192.9134.2120.8143.4186.2311.6154.5361.1208.3261.7275.9410.688-331.92
0.20.72.64.40.90.72.617.20.91.30.31.52.37.15.99.27.510.414.717.713.242.935.852.668.74
00.11.45.72.622.13.62.41.21.41.71.31.95.47.1101116.829.360.570.674.998.8136.4154.28
0.100.10.10.30.30.40.30.10.40.60.50.60.20.10.10.40.70.70.61.50.30000
00000000000000000000000000
0000000001.31.60.20.10.13.13.303.10001.21.10.61.22.61
0.30.84.110.23.835.14.99.73.84.92.73.54.515.716.419.622.327.944.679.785.3118.9135.2190.2225.63
00000000.010000000.020.020.020.020.050.060.320.360.370.581.151.18
00000000000000000000000000
001.81.710.60.711.62.22.2000.90.60.40.10.60.70.8039.930.4117.2223.4253.79
00000000.010000000.020.020.030.020.060.060.320.40.40.71.381.44
000.010.01000.010.010.010.010.01000.010.030.030.040.040.080.10.40.480.520.831.571.66
0.010.010.10.070.030.030.010.020.030.0200.130.20.140.150.180.230.360.240.460.60.740.81.241.661.33
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Insmed provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Insmed's financial health and stability.

Assets

Insmed's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Insmed must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Insmed after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Insmed's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-3-4-7-79-37-36-10-27-40-56-19-15118-6-59-41-56-79-118-176-192-324-254-294-434-481-749
000010001230100000112241015151213
000000000000000000000000000
00023-50204-61-5-11701081115-62-2-586-39
00055017000502-12202951723313636718398160119314
000000001000000011235679101035
0000000000002-100-19300000111
-3-4-7-21-31-24-10-24-27-42-25-11-11-7-30-31-46-64-100-146-159-257-250-219-363-400-536
000-100000-50000000-5-3-4-3-14-42-6-7-9-13
00-4-411000-2-1781218534611-5-3-4-3-14-42-6-64-34-223
00-4-311000-2-12812185356120000000-57-24-210
000000000000000000000000000
000000003500-2-1001904030039200337500-1
31409700128052180400256811022813818280271291311170
31409700124375218-2200456811522730381386285271612793168
0000000-32000000000000-1440-16-18-1
000000000000000000000000000
09-1171-20-232-206-61-110-14752345123-120218113-745184357-591
-3.51-4.74-7.34-22.71-32.03-24.08-10.76-24.9-27.77-47.22-25.26-11.99-11.01-7.72-31.19-31.3-47.49-69.77-104.15-150.91-162.62-272.79-292.92-226.17-370.59-410.32-549.54
000000000000000000000000000

Insmed stock margins

The Insmed margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Insmed. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Insmed.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Insmed's sales revenue. A higher gross margin percentage indicates that the Insmed retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Insmed's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Insmed's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Insmed's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Insmed. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Insmed's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Insmed Margin History

Insmed Gross marginInsmed Profit marginInsmed EBIT marginInsmed Profit margin
2029e78.52 %0 %26.81 %
2028e78.52 %29.89 %18.88 %
2027e78.52 %7.99 %1.04 %
2026e78.52 %-30.67 %-33.82 %
2025e78.52 %-113.44 %-120.3 %
2024e78.52 %-191.01 %-212.12 %
202378.52 %-223.1 %-245.59 %
202277.51 %-194.82 %-196.21 %
202176.55 %-195.12 %-230.61 %
202075.73 %-161.31 %-178.89 %
201982.27 %-172.31 %-186.3 %
201875.51 %-3,135.71 %-3,309.18 %
201778.52 %0 %0 %
201678.52 %0 %0 %
201578.52 %0 %0 %
201478.52 %0 %0 %
201378.52 %-478.26 %-487.83 %
201278.52 %0 %0 %
201178.52 %-811.36 %-1,563.64 %
201078.52 %-117.39 %-92.75 %
2009100 %-83.65 %1,138.46 %
2008100 %-123.08 %-134.19 %
200792.11 %-268.42 %-263.16 %
2006-50 %-4,730 %-5,610 %
2005100 %-27,400 %-40,900 %
2004100 %-27,400 %-27,200 %

Insmed Stock Sales Revenue, EBIT, Earnings per Share

The Insmed earnings per share therefore indicates how much revenue Insmed has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Insmed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Insmed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Insmed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Insmed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Insmed Revenue, EBIT and net profit per share

DateInsmed Sales per ShareInsmed EBIT per shareInsmed Earnings per Share
2029e17.96 undefined0 undefined4.81 undefined
2028e13.6 undefined0 undefined2.57 undefined
2027e9.44 undefined0 undefined0.1 undefined
2026e6.17 undefined0 undefined-2.09 undefined
2025e3.29 undefined0 undefined-3.96 undefined
2024e2.21 undefined0 undefined-4.69 undefined
20232.17 undefined-4.85 undefined-5.34 undefined
20222 undefined-3.89 undefined-3.91 undefined
20211.68 undefined-3.28 undefined-3.88 undefined
20201.68 undefined-2.72 undefined-3.01 undefined
20191.61 undefined-2.78 undefined-3.01 undefined
20180.13 undefined-4 undefined-4.22 undefined
20170 undefined-2.84 undefined-2.89 undefined
20160 undefined-2.8 undefined-2.85 undefined
20150 undefined-2.01 undefined-2.02 undefined
20140 undefined-2.03 undefined-1.84 undefined
20130.33 undefined-1.57 undefined-1.6 undefined
20120 undefined-1.6 undefined-1.56 undefined
20110.19 undefined-1.53 undefined-2.95 undefined
20100.05 undefined-0.06 undefined-0.05 undefined
20090.82 undefined-0.69 undefined9.32 undefined
20080.96 undefined-1.18 undefined-1.29 undefined
20070.66 undefined-1.77 undefined-1.74 undefined
20060.11 undefined-4.98 undefined-5.91 undefined
20050.02 undefined-5.59 undefined-8.35 undefined
20040.03 undefined-7.03 undefined-6.97 undefined

Insmed business model

Insmed Inc is a biopharmaceutical company that was founded in Virginia in 1999 by Dr. Melvin Sharoky. The company specializes in researching, developing, and marketing therapies for rare and serious lung diseases and immune system disorders. Insmed's business model is based on a solid scientific foundation and has a broad network of experienced researchers and clinical experts. The company aims to develop innovative therapies for unmet medical needs in the market. Insmed focuses on the treatment of niche diseases and related medical needs. The company is divided into two divisions: lung diseases and immunology. The lung diseases division includes the drug ARIKAYCE®, which was developed for patients with a specific form of pneumonia called very severe persistent Mycobacterium avium complex lung disease (vPSMAC). ARIKAYCE® is the first approved drug for this type of lung disease. In addition, Insmed is working on the development of therapies for other lung diseases such as non-tuberculous mycobacterial (NTM) lung disease and bronchiectasis. Insmed's immunology division focuses on the development of therapies for rare immune disorders such as autoinflammatory diseases (AID) and respiratory allergies. Insmed recently developed a drug called Bautista™, which focuses on the treatment of NLRC4 deficiency, a very rare and serious genetic disease. Insmed is constantly working to advance its science in order to develop new and innovative therapies for rare diseases. The company makes significant investments in research and development, which is a key pillar of its business success. In 2018, the company received approval for ARIKAYCE® from the US Food and Drug Administration (FDA), leading to a successful market entry. Insmed is also actively working with regulatory authorities in Europe and Asia to obtain approval for ARIKAYCE® and increase international distribution. Today, Insmed is a globally operating company that has a broad impact on the healthcare industry. It believes in its scientific expertise and works hard to develop innovative therapies to help patients with rarer disease conditions achieve a better quality of life. Insmed is one of the most popular companies on Eulerpool.com.

Insmed SWOT Analysis

Strengths

Insmed Inc has several strengths that contribute to its success. One major strength is its innovative product portfolio, which includes unique and effective treatments. The company's strong research and development capabilities allow it to continuously develop new products and stay ahead of the competition. Additionally, Insmed Inc has a strong financial position and a solid track record of revenue growth.

Weaknesses

Despite its strengths, Insmed Inc also faces some weaknesses that need to be addressed. One major weakness is its heavy reliance on key suppliers for raw materials and components. Any disruption in the supply chain can significantly impact the company's operations. Moreover, the company has limited geographical diversification, relying heavily on a few key markets for its revenue.

Opportunities

Insmed Inc has various opportunities to capitalize on. The increasing prevalence of chronic diseases presents a growing market for the company's products. By expanding its product portfolio and penetrating new geographic markets, Insmed Inc can further fuel its growth. Additionally, advancements in technology and the rise of digital healthcare open doors for the company to explore innovative solutions and enhance its market presence.

Threats

Insmed Inc faces certain threats that may impact its business. One significant threat is the intense competition within the pharmaceutical industry. The presence of well-established competitors with similar offerings poses a challenge to Insmed Inc's market share. Additionally, regulatory changes and stringent approval processes for new drugs can hinder the company's ability to bring products to market quickly.

Insmed Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Insmed historical P/E ratio, EBIT, and P/S ratio.

Insmed shares outstanding

The number of shares was Insmed in 2023 — This indicates how many shares 140.433 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Insmed earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Insmed's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Insmed’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Insmed's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Insmed Stock splits

In Insmed's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Insmed.

Insmed latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.29 -1.94  (-50.18 %)2024 Q2
3/31/2024-1.26 -1.06  (15.57 %)2024 Q1
12/31/2023-1.17 -1.28  (-9.49 %)2023 Q4
9/30/2023-1.15 -1.11  (3.86 %)2023 Q3
6/30/2023-1.15 -1.78  (-54.31 %)2023 Q2
3/31/2023-1.13 -1.17  (-3.1 %)2023 Q1
12/31/2022-1.06 -1.21  (-14.32 %)2022 Q4
9/30/2022-0.9 -1.09  (-20.5 %)2022 Q3
6/30/2022-0.91 -0.8  (12.03 %)2022 Q2
3/31/2022-0.9 -0.8  (11.35 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the Insmed stock

Eulerpool World ESG Rating (EESG©)

47/ 100

🌱 Environment

20

👫 Social

81

🏛️ Governance

41

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Insmed list of shareholders

%
Name
Stocks
Change
Date
8.64 % The Vanguard Group, Inc.14,096,512-313,84412/31/2023
6.46 % T. Rowe Price Associates, Inc.10,539,825378,04312/31/2023
6.33 % BlackRock Institutional Trust Company, N.A.10,330,1321,036,60712/31/2023
3.64 % State Street Global Advisors (US)5,929,933875,55012/31/2023
3.59 % T. Rowe Price Investment Management, Inc.5,850,606-2,474,27812/31/2023
3.38 % Palo Alto Investors LP5,511,721-377,77012/31/2023
3.28 % Deep Track Capital LP5,350,000-650,00012/31/2023
2.85 % Macquarie Investment Management4,651,492-2,28012/31/2023
2.80 % Fidelity Management & Research Company LLC4,572,391783,25012/31/2023
2.61 % William Blair Investment Management, LLC4,256,68714,75212/31/2023
1
2
3
4
5
...
10

Insmed Executives and Management Board

Mr. William Lewis54
Insmed Chairman of the Board, President, Chief Executive Officer (since 2012)
Compensation 7.79 M
Mr. Roger Adsett54
Insmed Chief Operating Officer
Compensation 4.64 M
Mr. Drayton Wise48
Insmed Chief Commercial Officer
Compensation 4.02 M
Dr. Martina Flammer59
Insmed Chief Medical Officer
Compensation 3.76 M
Ms. Sara Bonstein42
Insmed Chief Financial Officer
Compensation 3.43 M
1
2
3
4

Insmed Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Ajinomoto Stock
Ajinomoto
SupplierCustomer0,410,760,810,62-0,01-0,55
AstraZeneca Stock
AstraZeneca
SupplierCustomer0,390,73-0,06-0,46-0,40-0,67
Thermo Fisher Scientific Stock
Thermo Fisher Scientific
SupplierCustomer0,290,650,620,790,34-0,39
American Software A Stock
American Software A
SupplierCustomer0,030,790,670,730,81-0,21
PPD, Inc. Stock
PPD, Inc.
SupplierCustomer-0,46-0,26-0,47-0,58-0,25-
1

Most common questions regarding Insmed

What values and corporate philosophy does Insmed represent?

Insmed Inc is a leading biopharmaceutical company committed to transforming the lives of patients with serious and rare diseases. With a strong corporate philosophy centered around innovation, collaboration, and patient-centricity, Insmed strives to deliver breakthrough therapies that address unmet medical needs. The company values integrity, scientific excellence, and empathy, aiming to make a positive impact on the lives of patients worldwide. Insmed Inc focuses on developing advanced therapies using its proprietary platform technologies and leveraging its extensive industry knowledge and expertise. By constantly pushing boundaries and advocating for patients, Insmed embodies a commitment to improving healthcare outcomes and enhancing the quality of life for those in need.

In which countries and regions is Insmed primarily present?

Insmed Inc is primarily present in the United States.

What significant milestones has the company Insmed achieved?

Insmed Inc, a leading biopharmaceutical company, has accomplished several significant milestones. In recent years, Insmed Inc received FDA approval for its breakthrough drug, ARIKAYCE®, a treatment for Mycobacterium avium complex (MAC) lung disease. This achievement marked a major breakthrough in respiratory medicine. Additionally, Insmed Inc has successfully advanced the development of novel therapies, such as brensocatib for bronchiectasis, establishing its position as a pioneer in the field. Through its dedication to scientific innovation and commitment to improving patient outcomes, Insmed Inc continues to achieve remarkable milestones, reinforce its reputation, and shape the future of the healthcare industry.

What is the history and background of the company Insmed?

Insmed Inc is a biopharmaceutical company headquartered in Bridgewater, New Jersey. Founded in 1988, Insmed focuses on the development and commercialization of therapies for serious and rare diseases. The company primarily concentrates on the discovery and development of novel drugs to address unmet medical needs, particularly in the field of severe lung diseases. Over the years, Insmed has made significant advancements in scientific research and clinical trials, resulting in the approval of its flagship product, ARIKAYCE®, for the treatment of Mycobacterium avium complex lung disease. With a strong commitment to innovation and improving patients' lives, Insmed Inc has established itself as a leading player in the biopharmaceutical industry.

Who are the main competitors of Insmed in the market?

The main competitors of Insmed Inc in the market include other pharmaceutical companies such as Gilead Sciences, Novartis, AstraZeneca, and GlaxoSmithKline. These companies operate in the same industry and compete with Insmed Inc in the development and commercialization of innovative therapies. Their products and services may overlap with Insmed Inc's, creating competition for market share and the pursuit of specific indications and patient populations. By staying informed about the activities and progress of these competitors, investors can gain insights into the dynamic landscape of the pharmaceutical industry and make more informed investment decisions.

In which industries is Insmed primarily active?

Insmed Inc is primarily active in the biopharmaceutical industry, specializing in the development and commercialization of novel therapies for patients with serious and rare diseases. With a focus on respiratory and infectious diseases, Insmed Inc aims to address unmet medical needs and improve the lives of patients. As a leading player in the biopharmaceutical sector, Insmed Inc is committed to advancing innovative solutions and creating value for shareholders, healthcare providers, and patients alike.

What is the business model of Insmed?

Insmed Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for patients with serious and rare diseases. The company's business model revolves around identifying unmet medical needs and utilizing innovative technologies to develop novel therapies. Insmed focuses on advanced lung diseases, including non-tuberculous mycobacterial lung disease (NTM) and severe bronchiectasis. By leveraging its expertise in this therapeutic area, Insmed aims to provide effective treatments to patients who lack adequate options. With a strong commitment to research and development, Insmed Inc strives to make a positive impact on the lives of patients and continually advance the field of biopharmaceuticals.

What is the P/E ratio of Insmed 2024?

The Insmed P/E ratio is -14.

What is the P/S ratio of Insmed 2024?

The Insmed P/S ratio is 29.69.

What is the AlleAktien quality score of Insmed?

The AlleAktien quality score for Insmed is 8/10.

What is the revenue of Insmed 2024?

The expected Insmed revenue is 360.44 M USD.

How high is the profit of Insmed 2024?

The expected Insmed profit is -764.55 M USD.

What is the business model of Insmed

Insmed Inc is a biopharmaceutical company focused on developing and marketing therapies for patients with rare lung diseases and serious infections. The company operates in three core business areas: product development, marketing of approved therapies, and diagnostic services. Insmed Inc invests heavily in research and development, particularly in the potential of inhalation drugs for targeted treatment of lung diseases such as cystic fibrosis and non-tuberculous mycobacterial infections. They also market approved therapies, like Arikayce, and offer diagnostic services with an innovative lung function diagnostic system. The goal of their business model is to create value for patients, doctors, and investors, positioning themselves as a leading company in this field. However, regulatory conditions may pose risks and delay the market entry of new therapies. Overall, Insmed Inc is an exciting company of great interest to investors and the medical community, contributing to saving lives and improving the quality of life for patients worldwide.

What is the Insmed dividend?

Insmed pays a dividend of 0 USD distributed over payouts per year.

How often does Insmed pay dividends?

The dividend cannot currently be calculated for Insmed or the company does not pay out a dividend.

What is the Insmed ISIN?

The ISIN of Insmed is US4576693075.

What is the Insmed WKN?

The WKN of Insmed is A1JJA3.

What is the Insmed ticker?

The ticker of Insmed is INSM.

How much dividend does Insmed pay?

Over the past 12 months, Insmed paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Insmed is expected to pay a dividend of 0 USD.

What is the dividend yield of Insmed?

The current dividend yield of Insmed is .

When does Insmed pay dividends?

Insmed pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Insmed?

Insmed paid dividends every year for the past 0 years.

What is the dividend of Insmed?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Insmed located?

Insmed is assigned to the 'Health' sector.

Wann musste ich die Aktien von Insmed kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Insmed from 8/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/21/2024.

When did Insmed pay the last dividend?

The last dividend was paid out on 8/21/2024.

What was the dividend of Insmed in the year 2023?

In the year 2023, Insmed distributed 0 USD as dividends.

In which currency does Insmed pay out the dividend?

The dividends of Insmed are distributed in USD.

All fundamentals about Insmed

Our stock analysis for Insmed Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Insmed Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.